Genecast Hopes for High IPO Valuation Despite Red Ink, Regulatory Risk
The maker of cancer diagnostics and testing products has made a second filing for a Hong Kong IPO, even as its industry faces regulatory risk due to the newness of…
RELATED ARTICLES
-
Kindstar Globalgene finds bargain in solid tumor testing acquisition
9960.HK -
Sinking Burning Rock faces de-listing. But could privatization bid come first?
BNR.US
-
So-Young dolls up with pivot to high-end services
SY.US
- Bayzed joins IPO quest as medical rivalry heats up
-
IFlytek hives off health unit to fund AI medical drive
002230.SHE
- Payment app Lianlian seeks IPO relief from cash crunch
- HealthyWay seeks Hong Kong IPO to staunch flow of red ink
